Details
- Autor(en) / Beteiligte
- Titel
- Equity Research: Novo Nordisk
- Ort / Verlag
- ProQuest Dissertations & Theses
- Erscheinungsjahr
- 2021
- Link zum Volltext
- Quelle
- ProQuest Dissertations & Theses A&I
- Beschreibungen/Notizen
- The aim of the thesis is that to asses show the future will unfold for the pharma company Novo Nordisk taking into account the entry of a disruptive and innovative competitor: Virta Health. As we will later further develop, Novo Nordisk has a strong pipeline of products, with its main focus on Diabetes. As we will later further develop, Novo Nordisk has a strong pipeline of products, with its main focus on Diabetes. Market potential for diabetes lies mainly in diabetes Type 2 which accounts for 90% to 95% of diabetes cases. Virt a strictly targets Type 2 diabetes, setting itself apart by reversing the disease or preventing it on a whole, without the use of medicines but through a dietary solution.Let me take you on this journey: together we will discover the secrets of diabetes and the pharma industry. Thanks to scientific innovation and research, new solutions and cures are being discovered as you read.
- Sprache
- Englisch
- Identifikatoren
- ISBN: 9798382480022Titel-ID: cdi_proquest_journals_3059393310
- Format
- –
- Schlagworte
- Annual reports, Biological products, Cardiovascular disease, Clinical trials, Diabetes, Discounted cash flow, Drugs, Endocrinology, FDA approval, Finance, Food, Growth rate, Health sciences, Hemophilia, Hormone replacement therapy, Insulin, Life expectancy, Market positioning, Market shares, Medicine, Obesity, Pharmaceutical industry, Pharmaceutical sciences, Public health, Stock prices, Therapy, Valuation, Weight control